501 exam 1

  1. Tonicity
    NS?
    • hypotonicity: 0.45% NS
    • isotonicity: 0.9% NS
    • hypertonicity: 3.0% NS
  2. Gain of H2O:
    hyponatremia
  3. Loss of Na+
    hyponatremia
  4. patho:
    Addison’s disease
    Decreased aldosterone secretion
    Diuretics
    Vomiting
    Diaphoresis
    Wounds
    • hyponatremia
    • LOSS OF Na+
  5. patho:
    SIADH
    Heart failure
    Polydipsia/Hyperglycemia
    Excess intake (IV, PO) fluids
    • EXCESS H2O
    • hyponatremia
  6. patho:
    Excessive PO Na+ intake
    Decreased water intake
    Sodium retention
    hypernatremia
  7. Gain of Na+
    hypernatremia
  8. Cushing’s Syndrome
    Hyperaldosteronism
    Renal Failure
    Sodium retention
  9. patho:
    Diabetes Insipidus
    Osmotic diuresis
    Burns
    Dehydration
    Fever/infection
    Diarrhea
    hypernatremia
  10. Loss of H2O
    hypernatremia
  11. Correct slowly (48 hours)
    Prevent cerebral edema
    Monitor Neuro
    hypernatremia
  12. Treat cause
    Lasix (due to poor KF)
    hypernatremia
  13. Restore normal serum Na+ levels
    Hypotonic IVF (0.225%)
    hypernatremia
  14. Nutrition
    Na+ restriction
    hypernatremia
  15. Nutrition
    Increase oral intake NaCl tabs
    hyponatremia
  16. Treat cause
    Decrease loop diuretics
    hyponatremia
  17. Restore normal serum Na+ levels
    Small volume hypertonic IVF (2%-3%) saline
    hyponatremia
  18. K+ regulation
    • Renal
    • Intracellular-extracellular shifts
  19. pressure exerted by proteins in the blood plasma or interstitial fluid.
    osmotic pressure
  20. force generated by the pressure of fluid within capillary on the capillary wall.
    Hydrostatic pressure
  21. Sodium polystyrene sulfonate (Kayexalate) has been used as an oral or rectal therapy for
    hyperkalemia
  22. intercellular shifts of glucose is common for ___________.
    hyperkalemia
  23. β2-agonist(s) that has a stimulatory effect on Na+/K+ ATPase and the resultant intracellular shift of potassium
    • Albuterol
    • D50 + Insulin IV
  24. Calcium Gluconate/Calcium Chloride prevents the deleterious cardiac effects of severe __________.
    • hyperkalemia
    • hypermagnesemia
  25. clinical manifestation: 
    Acute weight loss
    Increased ADH secretion
    Increased serum osmolarity
    Decreased vascular volume
    fluid volume deficit
  26. labs
    Increased hematocrit
    Increased BUN
    (blood urea nitrogen)
    Increased spec. gravity
    fluid volume deficit
  27. S/S
    Decreased urine output
    Tachycardia
    Postural hypotension
    Elevated temperature
    Fluid Volume Deficit
  28. Manifestations
    Acute, rapid weight gain
    Peripheral edema
    Increased interstitial fluid
    U/O- polyuria
    Increase vascular volume
    Fluid volume excess
  29. Labs
    Dilutional hyponatremia
    Dilutional anemia
    Hematocrit decreased
    BUN decreased
    Fluid volume excess
  30. s/s
    Dependent edema
    Generalized edema
    Pulmonary edema
    Jugular Vein Distention
    fluid volume excess
  31. causes:
    Diabetes Insipidus
    Osmotic diuresis
    Burns
    Dehydration
    Fever/infection
    Diarrhea
    • hyernatremia 
    • water loss
  32. causes:
    Decreased water intake
    Sodium retention
    Cushing’s Syndrome
    Hyperaldosteronism
    Renal Failure
    • hypernatremia
    • increased Na+
  33. HCO3- retention 
    loss of K+ & H+
    • metabolic alkalosis
    • hyperaldosterism
  34. hypomagnesium
    hypernatremia
    • metabolic acidosis
    • DM + ketabolic acidosis
  35. causes
    Diuretics
    Alcoholism
    GI
    Laxative abuse
    Hyperglycemia
    DKA
    HHNS
    Gastric Suctioning
    Massive Burns
    hypomagnesemia
  36. what causes decreased aldosterone secretion?
    hyponatremia
  37. Addison’s disease 
    Tx
    hyponatremia
  38. Hyperglycemia vs DKA
    hyponatremia
  39. DI
    hypernatremia
  40. SIADH
    Hyponatremia
  41. low Hydrostatic Pressure
    cause of edema
  42. Venous Obstruction
    • cause of edema -->
    • hydrostatic pressure
  43. low Capillary Colloidal Pressure
    • cause of edema -->
    • plasma proteins
  44. Loss of plasma proteins
    • cause of edema -->
    • plasma proteins
  45. Production of plasma proteins
    cause of edema
  46. high Vascular Volume
    • cause of edema -->
    • hydrostatic pressure
  47. Ischemia & cell death/necrosis
    edema
  48. release of ______ results in efferent arteriole vasoconstriction.
    renin
  49. Release of renin results in ______ arteriole vasoconstriction.
    efferent
  50. vasoconstriction of the efferent arteriole in the kidneys results in __________.
    increase in blood pressure
  51. angiotensin II triggers _______ at the adrenal cortex
    Aldosterone
  52. angiotensin II triggers Aldosterone in the _______
    adrenal cortex
  53. aldosterone produces
    1
    2
    3
    • 1) efferent arterial blood pressure
    • 2) increase in vascular volume due to vasoconstriction
    • 3) Na+ retention
  54. Na+ controls _______ fluid
    extracellular
  55. 1.6 to 2.6 mg/dL
    NORMALS for Mg+
  56. 135-145 mEq/L
    NORMALS for Na+
  57. 3.5-5.0 mEq/L
    NORMALS for Na+
  58. 7.35-7.45
    normal pH
  59. 35-45
    PaCO2
  60. 22-26 mEq/L
    bicarbonate
  61. anemia + hyperventiation
    respiratory alkalosis
  62. COPD + hypoventilation
    respiratory acidosis
  63. diuresis + hypernatremia
    metabolic acidosis
  64. hypokalemia
    hypernatremia 
    diuresis
    hyperaldosterism
    metabolic alkalosis
  65. hyponatremia + edema
    SIADH
  66. high SG
    low u/o
    SIADH
  67. low SG
    high u/o
    DI
  68. hypernatremia + polyruria
    DI
  69. what cause increased ADH secretion
    fluid deficit
  70. cushings syndrome
    • hypernatremia
    • hypokalemia
  71. addison's disease
    • hyponatremia
    • Decreased aldosterone secretion
  72. -zudin
    NRTI
  73. blocking RNA strand
    NRTI
  74. AZT
    NRTI
  75. MAO:
    inhibits human DNA
    NRTI
  76. bone marrow suppression
    CP450 
    hepatotoxic
    NRTI
  77. -gravir
    INSTI
  78. Blocks integration of viral DNA
    INSTI
  79. there is one opportunity for this HIV drug to be effective
    INSTI
  80. attachment inhibitors
    maraviroc
  81. blocks HIV receptors so they cannot bind
    attachment inhibitors
  82. RNA inhibitor
    NNRTI
  83. bind to RT
    NNRT
  84. inhibits human DNA
    NNRTi
  85. steven johnson syndrome HIV
    NNRTI
  86. HIV
    hyperglycemia
    PI
  87. internalization
    fusion inhibitors
  88. cuts up protein
    PI
  89. PI MAO
    cleavage
  90. INSTI MAO
    Integration
  91. RTIs MAO
    DNA synthesis
  92. entry inhibitors 
    MAO
    • Attachment 
    • fusion
  93. aldosterone vs ADH
    increase Na+ vs  increase H2O
  94. Addisons vs Cushings
    decrease Na+ vs increase Na+
  95. indications for neuromuscular blockers
    adjunct to anesthesia
  96. blocks Ach --> nicotinicM receptors
    Panuronium
  97. panuronium
    nonpolarizing neuromuscular blocker
  98. polarizing neuromuscular blocker
    succinycholine
  99. agonist to nicotinicM receptors
    succinylcholine
  100. side effects of these drugs are that they trigger a histamne release, resulting in hypotension
    neuromuscular blockers
  101. Adverse effects
    Headache
    Reflex bradycardia
    Reslessness and excitability
    Phenylephrine
  102. alpha 1 agonist
    phenyephrine
  103. Alpha 2 adrenergic receptors
    Clonidine
  104. inhibits norepinephrine
    clonidine
  105. Selectively activates alpha 2 receptors in CNS where autonomic regulation of C-V system occurs (brainstem)
    clonidine
  106. stimulates sympathetic outflow to blood vessels and heart is reduced
    clonidine
  107. BETA 1 Receptor
    dobutamine
  108. Stimulation results in:
    increased heart rate, force, automaticity, conduction rates
    lipolysis
    renin release
    dobutamine
  109. positive inotropic 
    positive chronotropic
    postive dromostropic
    dobutamine
  110. Used during and following cardiac surgery, CHF, low CO states, shock
    Given IV
    dobutamine
  111. Contraindications:
    Angina, CAD, heart monitor
    dobutamine
  112. Adverse effects
    Tachycardia
    Chest pain, hypotension
  113. Stimulation results in:
    Bronchodilitation
    Vasodilitation
    Slight decrease in peripheral resistance
    Relaxation of pregnant uterus
    Glycogenolysis
    Release of glucagon
    albuterol
  114. Used to treat
    asthma, bronchospasm, COPD, CHF, CF
    albuterol
  115. Nonselective adrenergic receptors
    Epinephrine
  116. Produces both alpha and beta effects
    epinephrine
  117. Used to Tx
    shock, asthma, CP resuscitation, heart blocks, simple glaucoma, adjunct to topical anesthesia, anaphylactic shock, GI hemorrhag
    epinephrine
  118. Given topically, IM, Sub Q, IV
    epinephrine
  119. Wide ranging effects depending upon receptor
    epinephrine
  120. Contraindications
    Hypersensitivity
    narrow-angle glaucoma
    labor
    coronary insufficiency
    epinephrine
  121. contraindicated w/ ventricular dysrhythmias, diabetes, Parkinson’s disease, & uncorrected hypovolemia
    epinephrine
  122. agonist for alpha and beta 1
    Norepinephrine
  123. Alpha-Adrenergic Blockers
    Phentolamine
  124. non-selective adrenergic antagonists
    phentolamine
  125. Selective alpha 1 blockade
    prazosin (minipress)
  126. MAO: vasodilation
    Tx: HTN
    ADR: orthostatic hypotension
    prazosin
  127. Beta Blockers
    • metorolol
    • propranolol
  128. cardioselective
    metorolol
  129. noncardioselective
    propranolol
  130. cardioselective only at therapeutic levels, at higher does will exhibit noncardioselectivity
    metorolol
  131. noncardioselective
    propranolol
  132. Used for BP and HR control
    Used more often than alpha blockers
    metorolol
  133. May also have alpha blockade property even at therapeutic levels
    metorolol
  134. how much do e have to give to illicit a response
    dose-response relationship
  135. max efficacy
    dose-response relationship
  136. receptor activation intensity
    dose-response relationship
  137. relative potency
    dose-response relationship
  138. what does the drug do at the site of acton
    drug-receptor interactions
  139. simple vs modified occupied theory
    drug-receptor interaction
  140. RN is only person whose actions are not routinely checked by others. A few exceptions
    A PINCH medications
  141. Threshold for detecting response is reached
    dose-response relationship
  142. largest effect that a drug can produce
    max efficacy
  143. Indicated by height of Dose-Response curve
    max efficacy
  144. bigger doses unable to elicit a further increase in response
    All receptors bound by drug
    max efficacy
  145. relative potency vs affinity
    • dose 
    • concentration
  146. potency is a difference in _______ whereas efficacy is a difference in _________.
    dose; response
  147. *bigger doses unable to elicit a further increase in response
    *All receptors bound by drug
    simple occupancy
  148. does not account for relative potency or max efficacy
    simple occupancy
  149. Reflected in drug’s maximal efficacy
    *Intrinsic activity
  150. Bind irreversibly to receptors
    noncompetitive antagonists
  151. Continual exposure to agonist
    Desensitized; tolerance
  152. down-regulation
    desensitized; tolerance
  153. Continual exposure to antagonist
    Hypersensitivity
  154. up-regulation
    hypersensitivity
  155. Dose required to produce a defined effect in 50% of population
    ED50
  156. movement of drug from blood to sites of action
    Distribution
  157. Drug molecules tend to accumulate on side where pH favors ionization
    pH partitioning
  158. Blood flow to tissues
    distribution
  159. movement across cell membranes
    distribution
  160. Polar, ionized, protein-bound= No
    lipid-soluble yes
    distribution
  161. Drug movement at the capillary bed
    distribution
  162. Blood Brain Barrier
    distribution
  163. chemical reactions --> metabolites
    Biotransformation
  164. study of a single gene’s role in the client’s response to drugs
    Pharmacogenetics
  165. study of how genes affect a client’s response to drugs
    Pharmacogenomics
  166. absorption
    first pass metobolism
    bioavailability
  167. Concentration gradient drives reabsorption of drug from lumen of tubule back into bloodstream
    passive tubular reabsorption
  168. Must be lipid soluble to cross tubular and vessel cell membranes
    passive tubular reabsorption
  169. Ionized and polar drugs remain in urine to be excreted
    passive tubular reabsorption
  170. Fluid & molecules move through capillary pores into tubular urine
    glomerular filtration
  171. Time required to eliminate 50% of total amount of drug in body
    half life
  172. An index of how rapidly a decline in drug occurs
    half life
  173. Reflection of metabolism and excretion
    half life
  174. The rate of drug eliminated depends on amount of drug present
    half life
  175. _______ of drug determines dosing intervals
    Half life
  176. Thiazide diuretics
    • Hydrochlorothiazide (HCTZ)
    • Chlorthalidone
  177. MAO
    Na+ excretion at distal tubs
    Decrease GFR
    blocks H2O reabsorption
    • HCTZ
    • chlorthalidone
  178. USE
    Hypernatremia
    Hyper/Hypokalemia
    • HCTZ
    • chlorthalidone
  179. Tx
    Edema
    HF
    preferred drug
    • HCTZ
    • chlorthalidone
  180. Adverse Effects
    Hypokalemia/hyperglycemia
    Hyponatremia/dehydration
    Orthostatic HTN
    • HCTZ
    • chlorthalidone
  181. DDI
    NSAIDS→ Reduced diuresis with what drugs?
    • HCTZ
    • chlorthalidone
  182. High-ceiling (loop) diuretic
    Furosemide (Lasix)
  183. MAO
    Na+ excretion at ascending loop of Henle
    furosemide (lasix)
  184. USE
    Hypernatremia
    Hyperkalemia
    Hypokalemia
    2nd-line HTN
    Edema
    furosemide (Lasix)
  185. diuretics indicated for renal impairment
    furosemide (lasix)
  186. diuretics contraindicated for Hyponatremia
    furosemide
  187. diuretics w ADR: ototoxicity
    furosemide (loop)
  188. NSAIDS = synergist to which diuretics
    furosemide (lasix)
  189. K+ Sparing diuretics
    Spironolactone (Aldactone)
  190. MAO
    Aldosterone receptor antagonists
    Prevent the re-absorption of Na+ @ the collecting duct
    spironolactone (Aldactone)
  191. USE
    Combo w/ thiazides & loops
    Effects are delayed
    spironolactone (Aldactone)
  192. Tx
    Edema
    spironolactone (Aldactone)
  193. Adverse effects
    Hyperkalemia
    spironolactone (Aldactone)
  194. diuretics that have Synergy w/
    ACE inhibitors
    ARBs
    spironolactone (aldactone)
  195. diuretics that are contraindicated with salt substitutes (KCl)
    spironolactone (Aldactone)
  196. Osmotic diuretics, Mannitol, may have ADR w/ what type fluid imbalance?
    • HYPERnatremia
    • water loss
  197. Treat cause
    Decrease loop diuretics
    HYPOnatremia
  198. Tx 
    when would you use Diuretics  (Lasix, HCTZ) w/ K+ sparing like Spironolactone?
    hypokalemia
  199. Only therapeutic use of irreversible agent
    • echothiophate
    • tx glaucoma
  200. Bone marrow depression, which leads to aplastic anemia and neutropenia, would also be ADR for which type of HIV drug
    NRTI
  201. -vir-
    NNRTI
  202. -vir
    PI
  203. lactic acidosis ADR w/ HIV drug_____.
    NRTI
  204. —Resistance: virus mutates gene encoding the glycoprotein è alters shape so drug can no longer bind
    Fusion inhibitor
  205. Reserved for patients who have failed more standard HAART (RTIs and PIs)
    fusion inhibitors
  206. only approved CCR5 antagonist
    attachment inhibitor
  207. SIADH vs DI
    • increased H2O, ADH, & SG
    • VS decreased H2O, ADH, & SG
  208. the rate at which red blood cells sediment in a period of one hour.
    erythrocyte sedimentation rate ESR
  209. It is a common hematology test, and is a non-specific measure of inflammation.
    ESR
  210. high ESR indicates what
    • acute infection
    • inflammatory diseases
    • blood cancers
Author
BodeS
ID
342635
Card Set
501 exam 1
Description
501
Updated